Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE: High-dose Almonertinib in EGFRm+ NSCLC with Brain Metastases
NCT04808752Phase 2Active, not recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-Free Survival at 26 months. Started Jul 2021; status: active, not recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04808752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808752.